Cero Therapeutics Secures $750K Convertible Note with Highly Dilutive Terms
CERO is trading near its 52-week low of $0.034 (2.9% above the low).
Summary
Cero Therapeutics Holdings, Inc. has issued and sold a convertible promissory note for $750,000, with a principal face value of $937,500, featuring highly dilutive conversion terms tied to market price.
Key Events · Financing and Capital Events · CERO
-
Convertible Note Issued
Cero Therapeutics issued and sold a convertible promissory note for a purchase price of $750,000, with a principal face value of $937,500, to Keystone Capital Partners, LLC.
-
Highly Dilutive Terms
The note is convertible into common stock at the lesser of $0.05 or 80% of the average of the five lowest intraday trading prices over 20 days, indicating significant potential dilution for existing shareholders.
-
Substantial Capital Raise
The $750,000 financing represents a substantial capital raise relative to the company's current valuation, highlighting a critical need for funding.
-
Trading Near 52-Week Lows
This dilutive financing occurs while the company's stock is trading near its 52-week low, exacerbating the impact on shareholder value.
Analysis · CERO · Life Sciences
This filing reports the actual issuance and sale of a significant convertible promissory note, representing over 100% of the company's current market capitalization. The note's conversion terms, which allow conversion at 80% of the lowest average trading prices, are highly unfavorable to existing shareholders and indicate a "death spiral" financing structure. This capital raise, occurring while the stock trades near its 52-week low, suggests the company is in a distressed financial position and is securing funding at a substantial cost to equity holders. The requirement to register shares for resale further adds to potential future dilution.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 42.1% of the 323 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CERO was trading at $0.04 on OTC in the Life Sciences sector, with a market capitalization of approximately $738.6K. The 52-week trading range was $0.03 to $588.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.